
Results
409
Companies which are more than 50% undervalued based on analyst price target.
409 companies
Zoetis
Market Cap: US$31.6b
Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
ZTS
US$76.29
7D
6.2%
1Y
-51.7%
Insmed
Market Cap: US$24.2b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$112.84
7D
5.8%
1Y
17.4%
Summit Therapeutics
Market Cap: US$12.4b
A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
SMMT
US$15.88
7D
9.0%
1Y
-30.9%
Praxis Precision Medicines
Market Cap: US$8.7b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$323.95
7D
-3.2%
1Y
592.8%
Vaxcyte
Market Cap: US$8.2b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$60.67
7D
4.4%
1Y
81.3%
Legend Biotech
Market Cap: US$5.4b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$27.68
7D
-4.2%
1Y
-26.2%
Caris Life Sciences
Market Cap: US$5.0b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$17.47
7D
-2.0%
1Y
-33.5%
Oruka Therapeutics
Market Cap: US$5.0b
A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
ORKA
US$84.50
7D
-11.2%
1Y
531.1%
Viking Therapeutics
Market Cap: US$4.5b
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
VKTX
US$42.13
7D
8.0%
1Y
39.5%
Structure Therapeutics
Market Cap: US$3.9b
A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
GPCR
US$56.63
7D
5.5%
1Y
202.3%
Dyne Therapeutics
Market Cap: US$3.8b
A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
DYN
US$23.83
7D
7.3%
1Y
184.0%
Kailera Therapeutics
Market Cap: US$3.0b
Operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
KLRA
US$22.24
7D
1.0%
1Y
n/a
Vera Therapeutics
Market Cap: US$2.9b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$42.96
7D
0.1%
1Y
86.8%
uniQure
Market Cap: US$2.8b
Develops treatments for patients suffering from rare and other devastating diseases in the United States.
QURE
US$41.41
7D
-10.1%
1Y
186.8%
BioCryst Pharmaceuticals
Market Cap: US$2.6b
A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
BCRX
US$10.99
7D
9.9%
1Y
25.0%
Mineralys Therapeutics
Market Cap: US$2.6b
A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
MLYS
US$30.46
7D
12.9%
1Y
118.4%
Intellia Therapeutics
Market Cap: US$2.5b
Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
NTLA
US$17.43
7D
3.0%
1Y
56.7%
Nektar Therapeutics
Market Cap: US$2.5b
A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
NKTR
US$74.90
7D
7.3%
1Y
229.5%
Kodiak Sciences
Market Cap: US$2.3b
A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
KOD
US$38.30
7D
-1.7%
1Y
882.1%
Ocular Therapeutix
Market Cap: US$2.3b
A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
OCUL
US$10.33
7D
9.1%
1Y
-4.0%
Generate Biomedicines
Market Cap: US$2.2b
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.
GENB
US$16.22
7D
-3.9%
1Y
n/a
Zai Lab
Market Cap: US$2.1b
A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
ZLAB
US$19.35
7D
1.8%
1Y
-44.6%
ADMA Biologics
Market Cap: US$2.1b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$9.21
7D
10.0%
1Y
-48.3%
Recursion Pharmaceuticals
Market Cap: US$2.1b
A clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
RXRX
US$3.84
7D
4.6%
1Y
-28.4%
Viridian Therapeutics
Market Cap: US$2.1b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$20.47
7D
11.4%
1Y
27.5%
Palvella Therapeutics
Market Cap: US$2.1b
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
PVLA
US$145.70
7D
5.4%
1Y
464.7%
Taysha Gene Therapies
Market Cap: US$2.0b
A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
TSHA
US$6.50
7D
-4.6%
1Y
168.6%
Precigen
Market Cap: US$2.0b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$5.51
7D
5.0%
1Y
190.0%
Syndax Pharmaceuticals
Market Cap: US$2.0b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$23.24
7D
6.3%
1Y
165.6%
Nuvation Bio
Market Cap: US$1.9b
A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
NUVB
US$5.67
7D
-0.2%
1Y
176.6%
Iovance Biotherapeutics
Market Cap: US$1.9b
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
IOVA
US$4.35
7D
4.6%
1Y
145.8%
Tyra Biosciences
Market Cap: US$1.8b
A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
TYRA
US$31.94
7D
0%
1Y
222.3%
AtaiBeckley
Market Cap: US$1.8b
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
ATAI
US$5.19
7D
-1.5%
1Y
97.3%
Bausch Health Companies
Market Cap: US$1.8b
Operates as a diversified specialty pharmaceutical and medical device company.
BHC
US$4.91
7D
-0.4%
1Y
-26.7%
Maze Therapeutics
Market Cap: US$1.8b
A clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
MAZE
US$32.84
7D
10.1%
1Y
118.1%
COMPASS Pathways
Market Cap: US$1.7b
Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.
CMPS
US$12.99
7D
-8.2%
1Y
275.4%